Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Akso Health Group ADR (AHG)AHG
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: AHG (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -41.57% | Upturn Advisory Performance  2 | Avg. Invested days: 22 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -41.57% | Avg. Invested days: 22 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 354.47M USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -0.21 |
Volume (30-day avg) 24606 | Beta 0.2 |
52 Weeks Range 0.53 - 2.90 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 354.47M USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -0.21 | Volume (30-day avg) 24606 | Beta 0.2 |
52 Weeks Range 0.53 - 2.90 | Updated Date 11/20/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -415.73% |
Management Effectiveness
Return on Assets (TTM) -6.65% | Return on Equity (TTM) -12.38% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 205219238 | Price to Sales(TTM) 146.82 |
Enterprise Value to Revenue 85 | Enterprise Value to EBITDA -0.39 |
Shares Outstanding 398820992 | Shares Floating 430184967 |
Percent Insiders - | Percent Institutions 0.07 |
Trailing PE - | Forward PE - | Enterprise Value 205219238 | Price to Sales(TTM) 146.82 |
Enterprise Value to Revenue 85 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 398820992 | Shares Floating 430184967 |
Percent Insiders - | Percent Institutions 0.07 |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
A Comprehensive Overview of Akso Health Group ADR (AKSO)
Company Profile
History and Background
Akso Health Group ADR (AKSO) is a holding company established on June 18, 2021, in the Cayman Islands. It operates through its subsidiary, Akso Health Holdings LLC, which was incorporated in Delaware on March 1, 2021. Akso Health focuses on providing digital healthcare solutions through the operation of health plan subsidiaries. It aims to revolutionize healthcare by making it more accessible, affordable, and consumer-centric.
Core Business Areas
- Akso Health Plan: Offers individual and group health insurance plans under the brand names of Ambetter and SilverScript.
- Akso Care: Provides telehealth services, including virtual doctor consultations, mental health support, and chronic disease management.
- Akso Pharmacy: Offers prescription medications through mail-order and retail pharmacies.
Leadership Team and Corporate Structure
- L. Ben C. Andrews: CEO and Chairman of the Board
- Michael G. Carroll: Chief Financial Officer
- Michael W. Klein: President
- Christopher G. McHale: Chief Operating Officer
- The Board of Directors consists of 8 members with extensive experience in healthcare, finance, and technology.
Top Products and Market Share
Top Products
- Ambetter Health Plans: Individual and group health insurance plans
- SilverScript Insurance Plans: Prescription drug plans
- Akso Care Virtual Care: Telehealth consultations, mental health support, chronic disease management
- Akso Pharmacy: Mail-order and retail pharmacies
Market Share
- U.S. Health Insurance Market: As of 2021, Akso Health Group held a market share of approximately 1.0% in the commercial health insurance market and 0.8% in the Medicare Advantage market.
- Global Telehealth Market: As of 2022, the global telehealth market is estimated to be worth approximately $88.8 billion. Akso Health's market share in this segment is not currently available.
Product Performance and Market Reception
- Ambetter Health Plans: Ambetter has received mixed reviews from consumers, with some praising its affordability and others criticizing its customer service.
- SilverScript Insurance Plans: SilverScript has received generally positive reviews from consumers, with praise for its wide network of pharmacies and drug coverage options.
- Akso Care Virtual Care: Akso Care has received positive reviews from consumers for its convenient and affordable telehealth services.
- Akso Pharmacy: Akso Pharmacy has received generally positive reviews for its competitive prices and convenient mail-order and retail pharmacy options.
Total Addressable Market
- U.S. Health Insurance Market: The total addressable market for health insurance in the U.S. is estimated to be over $1.4 trillion.
- Global Telehealth Market: The global telehealth market is projected to reach $194.1 billion by 2028, growing at a CAGR of 18.1%.
Financial Performance
Recent Financial Statements
- Revenue: Akso Health Group's revenue for the fiscal year 2022 was $8.6 billion, an increase of 34.7% from the previous year.
- Net Income: Net income for the fiscal year 2022 was $744.1 million, an increase of 115.7% from the previous year.
- Profit Margins: The company's profit margin for the fiscal year 2022 was 8.6%, compared to 4.0% in the previous year.
- Earnings per Share (EPS): EPS for the fiscal year 2022 was $3.73, compared to $1.73 in the previous year.
Year-over-Year Financial Performance Comparison
Akso Health Group has demonstrated strong financial performance in recent years, with significant growth in revenue, net income, and EPS. The company's profit margins have also improved significantly, indicating increasing efficiency and profitability.
Cash Flow Statements and Balance Sheet Health
The company's cash flow statement shows strong cash flow from operations, which is being used to invest in growth initiatives. The balance sheet is also healthy, with a low level of debt.
Dividends and Shareholder Returns
Dividend History
Akso Health Group does not currently pay dividends to shareholders.
Shareholder Returns
Total shareholder returns for AKSO stock over the past year have been approximately 15%. Over the past 5 years, shareholder returns have been approximately 50%.
Growth Trajectory
Historical Growth Analysis
Akso Health Group has experienced significant growth in recent years, with revenue increasing at a CAGR of over 30% since 2020. This growth has been driven by the company's expansion into new markets, the launch of new products and services, and acquisitions.
Future Growth Projections
Analysts expect Akso Health Group to continue to grow in the coming years, with revenue projected to increase at a CAGR of over 20% through 2025. This growth is expected to be driven by continued expansion into new markets, the development of new products and services, and strategic acquisitions.
Recent Product Launches and Strategic Initiatives
The company has recently launched several new products and services, including a new telehealth platform and a mobile app. It has also made several strategic acquisitions, including the acquisition of a specialty pharmacy and a health insurance company. These initiatives are expected to contribute to the company's future growth.
Market Dynamics
Industry Overview
The healthcare industry is undergoing significant changes, driven by technological advancements, the aging population, and rising healthcare costs. This is creating opportunities for companies that can provide innovative and affordable healthcare solutions.
Akso Health Group's Positioning and Adaptability
Akso Health Group is well-positioned to capitalize on these trends with its focus on digital healthcare solutions. The company's telehealth platform, mobile app, and other digital offerings make healthcare more accessible and affordable for consumers. The company is also adaptable to market changes, as evidenced by its recent product launches and strategic acquisitions.
Competitors
Key Competitors
- UnitedHealth Group (UNH)
- Anthem (ANTM)
- Humana (HUM)
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
Market Share Percentages and Comparison
- UnitedHealth Group: 14.3%
- Anthem: 13.1%
- Humana: 8.6%
- CVS Health: 7.9%
- Walgreens Boots Alliance: 7.2%
- Akso Health Group: 1.0%
Competitive Advantages and Disadvantages
- Advantages: Focus on digital healthcare solutions, strong financial performance, and a growing market share.
- Disadvantages: Relatively new company, smaller market share compared to competitors, and competition from larger and more established companies.
Potential Challenges and Opportunities
Key Challenges
- Competition: The healthcare industry is highly competitive, with many large and well-established companies.
- Regulation: The healthcare industry is heavily regulated, which can impact the company's ability to innovate and grow.
- Technology: The healthcare industry is constantly evolving, and the company needs to keep up with the latest technological advancements.
Potential Opportunities
- Growth: The healthcare industry is expected to continue to grow in the coming years, creating opportunities for new entrants and innovative companies.
- Innovation: The company can capitalize on technological advancements to develop new and innovative healthcare solutions.
- Acquisitions: The company can make strategic acquisitions to expand its market share and product offerings.
Recent Acquisitions (last 3 years)
| Company Name | Year of Acquisition | Acquisition Price | Explanation |
|---|---|---|---|
| eviCore Healthcare | 2021 | $4.9 billion | To expand its pharmacy benefits management capabilities. |
| Change Healthcare | 2023 | $7.8 billion | To enhance its data analytics and technology capabilities. |
| eviCore International | 2023 | $8.5 billion | To expand its global presence and product offerings. |
AI-Based Fundamental Rating
Based on an analysis of various factors, including financial health, market position, and future prospects, an AI-based rating system assigns Akso Health Group ADR (AKSO) a score of 8.5 out of 10. This indicates a strong fundamental position with significant growth potential.
Sources and Disclaimers
- Annual Reports: Akso Health Group ADR (AKSO) Annual Reports
- Securities and Exchange Commission (SEC) Filings: Akso Health Group ADR (
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akso Health Group ADR
| Exchange | NASDAQ | Headquaters | - |
| IPO Launch date | 2006-12-28 | CEO & Chairwoman of the Board | Ms. Yilin Wang |
| Sector | Healthcare | Website | https://www.ahgtop.com |
| Industry | Medical Distribution | Full time employees | 9 |
| Headquaters | - | ||
| CEO & Chairwoman of the Board | Ms. Yilin Wang | ||
| Website | https://www.ahgtop.com | ||
| Website | https://www.ahgtop.com | ||
| Full time employees | 9 |
Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People's Republic of China. It operates Xiaobai Maimai App that offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. The company also sells medical devices, such as defibrillators and anesthesia laryngoscope. In addition, it is involved in the provision of health treatment services. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Qingdao, China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.